Opthea Limited Unsponsored ADR (NASDAQ:OPT) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Opthea Limited's Unsponsored ADR (NASDAQ:OPT) has received an average recommendation of "Hold" from seven analysts, with ratings that include two sell, four hold, and one strong buy.
• Institutional investors own 55.95% of Opthea's stock, with significant increases in stakes from firms like Regal Partners Ltd and Twin Lakes Capital Management LLC during the first quarter.
• The stock's current trading price is $3.41, with a 12-month low of $1.79 and a high of $6.30.

Shares of Opthea Limited Unsponsored ADR (NASDAQ:OPT - Get Free Report) have earned an average recommendation of "Hold" from the seven ratings firms that are covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and one has given a strong buy rating to the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $1.3333.

Separately, Weiss Ratings reiterated a "sell (e+)" rating on shares of Opthea in a research report on Saturday, September 27th.

Institutional Investors Weigh In On Opthea

Large investors have recently added to or reduced their stakes in the business. Regal Partners Ltd lifted its stake in Opthea by 78.6% during the first quarter. Regal Partners Ltd now owns 5,193,688 shares of the company's stock worth $17,710,000 after purchasing an additional 2,286,285 shares during the last quarter. Twin Lakes Capital Management LLC lifted its stake in Opthea by 67.4% during the first quarter. Twin Lakes Capital Management LLC now owns 33,156 shares of the company's stock worth $113,000 after purchasing an additional 13,350 shares during the last quarter. Citadel Advisors LLC bought a new stake in shares of Opthea in the 4th quarter valued at about $79,000. OLD Mission Capital LLC lifted its stake in shares of Opthea by 78.7% in the 1st quarter. OLD Mission Capital LLC now owns 19,167 shares of the company's stock valued at $65,000 after acquiring an additional 8,439 shares during the last quarter. Finally, EP Wealth Advisors LLC bought a new stake in shares of Opthea in the 1st quarter valued at about $34,000. Institutional investors own 55.95% of the company's stock.

Opthea Stock Performance

NASDAQ:OPT traded up $0.23 during trading hours on Friday, reaching $3.41. The stock had a trading volume of 3,000 shares. The stock has a 50 day simple moving average of $3.41 and a 200 day simple moving average of $3.41. Opthea has a 12-month low of $1.79 and a 12-month high of $6.30.

Opthea Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.